Keith Manchester - Sep 10, 2025 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)

Role
Director
Signature
By: /s/ Jo Chen, as Attorney-in-Fact for Keith Manchester
Stock symbol
ROIV
Transactions as of
Sep 10, 2025
Transactions value $
$0
Form type
4
Date filed
9/12/2025, 09:00 PM
Previous filing
Jun 27, 2025
Next filing
Nov 21, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
MANCHESTER KEITH S Director C/O ROIVANT SCIENCES LTD., 7TH FLOOR, 50 BROADWAY, LONDON, UNITED KINGDOM By: /s/ Jo Chen, as Attorney-in-Fact for Keith Manchester 2025-09-12 0001244828

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ROIV Common Shares Award $0 +14.5K +0.75% $0.00 1.95M Sep 10, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ROIV Stock Option (Right to Buy) Award $0 +33.7K $0.00 33.7K Sep 10, 2025 Common Shares 33.7K $13.77 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date.
F2 Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date.